Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.37 -1.2%	$3.35	$2.71 ▼ $4.73	$653.11M	1.23	965,474 shs	1.81 million shs
CDXC ChromaDex		$6.16	$2.31 ▼ $9.18	$611.50M	2.21	827,665 shs	554,788 shs
TNGX Tango Therapeutics	$5.36 +0.8%	$2.53	$1.03 ▼ $12.02	$576.66M	1.24	1.51 million shs	3.04 million shs
TRVI Trevi Therapeutics	$5.77 +0.3%	$6.35	$2.36 ▼ $7.48	$674.43M	0.59	1.38 million shs	1.11 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.17%	-2.32%	+4.66%	+0.60%	+9.77%
CDXC ChromaDex	0.00%	0.00%	0.00%	0.00%	+208.43%
TNGX Tango Therapeutics	+0.75%	+11.67%	+191.30%	+248.05%	-47.19%
TRVI Trevi Therapeutics	+0.35%	-5.72%	-8.27%	-10.82%	+118.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	1.5221 of 5 stars	3.5	0.0	0.0	0.6	2.5	0.6
CDXC ChromaDex	2.7108 of 5 stars	3.5	0.0	4.0	0.6	0.0	1.9
TNGX Tango Therapeutics	2.0105 of 5 stars	3.5	1.0	0.0	3.2	1.7	0.0
TRVI Trevi Therapeutics	1.7155 of 5 stars	3.7	2.0	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	63.20% Upside
CDXC ChromaDex	3.00	Buy	$9.03	∞ Upside
TNGX Tango Therapeutics	3.00	Buy	$12.20	127.61% Upside
TRVI Trevi Therapeutics	3.33	Buy	$20.29	251.57% Upside

Current Analyst Ratings Breakdown

Latest TNGX, ABUS, TRVI, and CDXC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	104.61	N/A	N/A	$0.51 per share	6.61
CDXC ChromaDex	$99.60M	0.00	N/A	N/A	$0.38 per share	0.00
TNGX Tango Therapeutics	$42.07M	13.81	N/A	N/A	$1.86 per share	2.88
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
CDXC ChromaDex	-$4.94M	$0.10	787.29	0.00	N/A	1.62%	4.85%	2.70%	N/A
TNGX Tango Therapeutics	-$130.30M	-$1.22	N/A	N/A	N/A	-322.67%	-62.75%	-39.94%	8/6/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.45	N/A	N/A	N/A	N/A	-58.41%	-52.52%	8/6/2025 (Estimated)

Latest TNGX, ABUS, TRVI, and CDXC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
CDXC ChromaDex	N/A	2.95	2.35
TNGX Tango Therapeutics	N/A	6.26	6.26
TRVI Trevi Therapeutics	N/A	15.38	15.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CDXC ChromaDex	15.41%
TNGX Tango Therapeutics	78.99%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
CDXC ChromaDex	9.64%
TNGX Tango Therapeutics	7.50%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
CDXC ChromaDex	120	77.75 million	69.02 million	Optionable
TNGX Tango Therapeutics	90	108.39 million	100.26 million	Optionable
TRVI Trevi Therapeutics	20	117.29 million	95.83 million	Optionable

TNGX, ABUS, TRVI, and CDXC Headlines

Recent News About These Companies

TRVI - Trevi Therapeutics Inc Key Metrics - Morningstar

June 25 at 12:16 AM | morningstar.com

Trevi Therapeutics Stockholders Approve Key Amendments

June 17, 2025 | tipranks.com

Q2 EPS Estimate for Trevi Therapeutics Lifted by Analyst

June 15, 2025 | americanbankingnews.com

Leerink Partnrs Has Bullish Forecast for TRVI Q2 Earnings

June 13, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Trading Down 4.8% - Time to Sell?

June 9, 2025 | marketbeat.com

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 9, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC

June 7, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

June 7, 2025 | marketbeat.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5, 2025 | prnewswire.com

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 5, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?

June 4, 2025 | marketbeat.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's Why

June 3, 2025 | marketbeat.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?

June 2, 2025 | marketbeat.com

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital

June 2, 2025 | marketbeat.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

June 1, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TRVI Q2 Earnings

May 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX, ABUS, TRVI, and CDXC Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.37 -0.04 (-1.17%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$3.42 +0.05 (+1.45%)

As of 06/24/2025 08:00 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Tango Therapeutics NASDAQ:TNGX

$5.36 +0.04 (+0.75%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$5.40 +0.03 (+0.65%)

As of 04:06 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Trevi Therapeutics NASDAQ:TRVI

$5.77 +0.02 (+0.35%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$5.78 +0.01 (+0.16%)

As of 04:05 AM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time